摘要
目的探讨微小RNA（miRNA-222、miRNA-181、miRNA-216）在肝癌患者血清中的异常表达及其临床价值。方法采用实时定量PCR方法检测广东省人民医院2009年6月至2010年9月收治的49例原发性肝癌患者首次确诊时的血清标本及25名正常人虹清中上述3个miRNAs的表达水平，并分析它们表达差异及其同肝癌临床病理参数、生存预后的关系。结果miR-181及miR-216在肝癌患者和正常人血清中表达差异均无统计学意义（均P〉0．05），而miR-222在肝癌患者血清中表达水平显著上调（6．1±6．6比1．2±0．6，P〈0．01）。以miR-222表达量上调的中位倍数（3倍）将49例肝癌患者分成低表达组（25例）和高表达组（24例）。miR-222的高表达同肝硬化（P〈0．01）、肿瘤数目（P=0．013）、门静脉癌栓（P=0．002）、TNM分期（P=0．020）相关，而与血清甲胎蛋白水平、肿瘤直径及乙肝表面抗原无关。Kaplan—Meier生存分析显示miR-222的高表达组患者的中位总生存期明显短于低表达组（8．7个月比16．5个月，P=0．036）。Cox比例风险模型显示TNM分期和miR-222表达水平是两个主要的独立预后因子。结论血清miR-222在肝癌患者表达上调，可能有助于肝癌患者的预后预测。
Objective To investigate the abnormal expression of microRNAs （miR-216, miR-222, miR-181 ） in the serum of patients with hepatocellular carcinoma （ HCC ） and its clinical significance. Methods Serum miRNAs expression was investigated in 49 patients with HCC and 25 healthy normal controls by using real-time PCR technique, and then correlations between miRNAs expression and the clinicopathological features and prognosis of HCC patients were evaluated. Results No differences were observed between the HCC patients and healthy controls with respect to the expressions of serum miR-181 and miR-216 （P 〉 0.05 ） , while miR-222 was found to be significantly overexpressed in HCC serum samples （6. 1 ±6. 6 vs 1.2 ＋0. 6, P 〈0. 01）. According to the median fold change of miR-222 （3-fold） in all HCC serum samples, we divided the 49 patients into two groups：a low expression group （25 patients） and a high expression group （24 patients）. High level of miR-222 expression was correlated with cirrhosis （P 〈 0. 01 ）, tumor number （ P = 0.013 ） , portal vein tumor thrombosis （ P = 0. 002） and TNM stage （ P = 0. 020）, while not correlated with serum alpha-fetoprotein level, tumor size and 14bsAg. Kaplan-Meier survival analysis showed that the median overall survival in the high miR-222 expression group was significantly shorter than that in the low expression group （8.7 months vs 16.5 months, P =0. 036）. In multivariate Cox analysis, TNM stage and serum miR-222 expression were two independent prognostic factors. Conclusion Serum miR-222, upregulated in HCC, maybe helpful in prognosis of HCC patients.
出处
《中华医学杂志》
CAS
CSCD
北大核心
2013年第23期1830-1832,共3页
National Medical Journal of China
基金
广东省科技计划项目（2009A030301009
2011A030400009）
关键词
肝肿瘤
血清
预后
Liver neoplasms
Serum
Prognosis
